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doi:10.1016/j.autrev.2011.11.024a b s t r a c ta r t i c l e i n f oAvailable online 3 December 2011 The number of human conditions that are currently considered to be autoimmune diseases (AID) has been
steadily growing over the past decades and it is now estimated that over 10 million people are affected in
the United States. One of the major shared features among AID is the predominance in the female sex
which in some cases changes with the age at disease diagnosis. Numerous hypotheses have been formulated
based on intuitive scientiﬁc backgrounds to justify this sex imbalance, i.e. sex hormones and reproductive
factors, fetal microchimerism, other sex-related environmental factors, a skewing of the X-chromosome inac-
tivation patterns, and major defects in sex chromosomes. Nevertheless, none of these hypotheses has thus far
gathered enough convincing evidence and in most cases data are conﬂicting, as well illustrated by the reports
on fetal microchimerism in systemic sclerosis or primary biliary cirrhosis. The present article will critically
discuss the main hypotheses (loss of mosaicism, reactivation, and haploinsufﬁciency) that have been pro-
posed based on ﬁndings in female patients with speciﬁc AID along with two additional mechanisms
(X-chromosome vulnerability and X-linked polyamine genes) that have been observed in AID models. Further,
recent data have signiﬁcantly shifted the paradigm of X chromosome inactivation by demonstrating that a large
number of genes can variably escape silencing on one or both chromosomes. As a result we may hypothesize
that more than one mechanism may contribute to the female susceptibility to tolerance breakdown while the
possibility that unknown factors may indeed protect men from AID should not be overlooked.
© 2011 Elsevier B.V. All rights reserved.Contents1. Of women and autoimmunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A531
2. Of X chromosomes and women . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A532
3. Of X chromosomes and female advantages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A533
4. Of X chromosomes and the onset of autoimmunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A533
4.1. Loss of mosaicism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A533
4.2. Reactivation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A534
4.3. Haploinsufﬁciency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A534
4.4. Epigenetics and polyamines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A535
5. The unifying hypothesis of X chromosome vulnerability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A535
6. Final remarks and future developments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A535
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A536nit, Department of Medicine,
, 20089 Rozzano (MI), Italy.
rights reserved.1. Of women and autoimmunity
Autoimmune diseases (AID) include a wide range of clinical phe-
notypes collected in over 70 different disorders which are believed
to affect over 5% of the world population and account for a signiﬁcant
part of the health care expenditures [1]. In general terms, AID can be
distinguished by the wide variability of tissue-speciﬁcity or systemic
involvement, age of onset, serum autoantibodies, and response to
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considered to outnumber differences in AID and the one feature
that is shared by the vast majority of these conditions is the uneven
distribution between sexes. This predominance of AID in the female
sex accounts for over 80% of patients being women in most autoim-
mune diseases, as illustrated in Table 1 [4,5]. Even though the female
predisposition to AID has been known for over a century, the causes
of this sex imbalance remain unknown and several different hypoth-
eses have been proposed in the last few years. A susceptible genetic
background is considered to be necessary but appears insufﬁcient to
explain both AID onset and the female predominance, while several
environmental factors have been suggested as additional players in
tolerance breakdown [6]. The proposed factors include sex hormones,
fetal microchimerism, sex-speciﬁc environmental factors, reproduc-
tive history, a skewed X-chromosome inactivation pattern, and
major defects of the sex chromosomes. However, none of these hy-
potheses has thus far gathered enough convincing data, and in most
cases reports are conﬂicting or burdened by technical limitations
[7]. It is our opinion, indeed, that one or more mechanisms should ac-
count for the female susceptibility to AID but that the same mecha-
nisms are likely to be shared by numerous conditions, thus
militating against most proposed factors which failed to be recapitu-
lated in different clinical settings. This is the case for sex hormones,
sex-related environmental factors, and fetal microchimerism which
will be brieﬂy discussed.
The effect of sex hormones on AID onset and perpetuation was
ﬁrst suggested by their immunomodulatory effects. In particular, the
reported role of estrogens in lymphocyte maturation/activation and
the synthesis of antibodies and cytokines [8–10] raised great interest.
Further, estrogen receptor (ER) ligands modulate both the innate and
adaptive immune responses, alter antigen presenting cell (APC)
quantitatively and qualitatively both in vivo and in vitro, and regulate
dendritic cell (DC) differentiation [11]. When these observations
were used as the background to determine the sex hormone proﬁle
of women with AID and controls, results were disappointing with dif-
ferences failing to reach statistical signiﬁcance or being inconsistent.
As an example of this unresolved dichotomy, we could note that spe-
ciﬁc AID arise at different ages and reproductive phases (albeit in
most cases following menopause) [12,13] while the higher estrogen
levels characterizing pregnancy are often associated with an amelio-
ration of several autoimmune diseases such as rheumatoid arthritis
(RA) or systemic lupus erythematosus (SLE) [14–16].
Speciﬁc environmental factors manifest different probability of
exposure in men and women. This is the case, for example, of theTable 1
Female to male ratio reported for autoimmune diseases. Diseases in which a male pre-
dominance is observed are italicized.
Autoimmune disease Female:male ratio
Addison's disease [1–5] 0.8–2.4
Antiphospholipid antibody syndrome [1–4] 5
Autoimmune chronic hepatitis [4–19] 7
Giant cell arteritis [1–5] 2.5
Graves' disease [33] 7
Hashimoto's disease [33] 5–18
Idiopathic thrombocytopenic purpura [1–5] 3
Multiple sclerosis [73] 2
Myasthenia gravis [1–4] 3
Myositis [1–5] 2
Pernicious anemia [1–5] 2
Primary biliary cirrhosis [90] 10
Primary sclerosing cholangitis [1–19] 0.6
Rheumatoid arthritis [30] 2
Sjogren's syndrome [1–5] 9
Systemic lupus erythematosus [73] 9
Systemic sclerosis [3–26] 5
Type 1 diabetes [4–31] 0.8–1.2xenobiotics found in cosmetic products such as hair dye or nail polish,
both of which have been associated with speciﬁc AID.
Similarly, urinary tract infections are more common in women and
bacteria associated with this type of infection have been proposed as
ideal candidates but a causative relation could not be proven possibly
due to the long latency between the infection and the AID onset. In
the case of primary biliary cirrhosis (PBC) these factors have been sug-
gested, among others, by epidemiological and experimental studies
[17–20] but, despite the most recent xenobiotic-induced murine
models [7,21], a mechanistic relation can only be hypothesized. Den-
dritic cells, for examples, are activated by components of hair dyes
[22] while phtalate (phthalate) included in nail polish may trigger
an SLE-like autoantibody response [23,24]. Finally, a role of sex chro-
mosomes in AID has been proposed based on several mechanisms in-
cluding fetal microchimerism, X chromosome inactivation patterns,
and X-chromosome monosomy and duplication. Fetal microchimerism
was ﬁrst suggested based on the observation that most AID manifest
their peak of incidence following the fertile period and maternal and
fetal cells are exchanged during pregnancy, leading to fetal cell persis-
tence (i.e. microchimerism) in themother. Chimeric fetal cells are often
hematopoietic and can differentiate into somatic cells in multiple or-
gans, potentially acting as targets for autoimmunity and resembling
graft versus-host disease after stem-cell transplantation. Microchimeric
cells were ﬁrst detected in peripheral blood mononuclear cells from
patients with systemic sclerosis [25], but other authors have failed to
reproduce these ﬁndings in the same disease [26] or in PBC [27]. Cumu-
latively, available data on the role of fetal microchimerism in autoim-
munity are weak or inconclusive, as naturally acquired fetal and
maternal microchimerism is not uncommon in healthy women [28].
Nevertheless, we note that the concept of chimerism has witnessed a
signiﬁcant evolution over the past years to overcome the simple persis-
tence of fetal cells [29] and now includes more complex and multi-
generational chimerisms found in AID [30] such as type 1 diabetes mel-
litus (T1DM) [31], rheumatoid arthritis [32], and autoimmune thyroid
disease [33] or in prototypic female-predominant types of cancer
[34]. The proposed role for changes in the X chromosome that may
trigger or predispose to autoimmunity will be discussed in further
details.
2. Of X chromosomes and women
The female karyotype includes two X chromosomes, one derived
from each parent, while men carry one maternal X and one paternal
Y chromosome. To avoid double dosage of X chromosome-derived
proteins in females, one of the X chromosomes is randomly silenced
during X chromosome inactivation (XCI), which occurs in the early
stages of female embryogenesis. Only X-chromosome pseudoautoso-
mal regions (i.e. those with a corresponding allele on the Y chromo-
some) were thought to escape inactivation and the classical view of
this whole chromosome silencing through DNA methylation has
been recently challenged and will be discussed in details below. In
the classical vision, however, the XCI process results in female cellular
mosaicism: in a female, approximately half of the cells express genes
derived from the maternal X chromosome and the other half express
genes derived from the paternal X chromosome (ratio close to 50:50
when XCI is random) [35]. The X chromosome has numerous genes
which, directly or indirectly, are involved in immunity, and naturally
occurring variations in one gene copy might result in two distinct al-
leles with different regulatory and response capacities. For females,
this means additional physiological diversity: not only do heterozy-
gous females avoid the effects of deleterious gene-mutations, they
also beneﬁt from added diversity when facing new immune chal-
lenges, such as microbial infections [36–38]. Thus, deleterious or dis-
advantageous mutations that occur in an X chromosome-linked gene
will result in the functional loss of the protein in all cells in a male, but
in only half of cells in a female. However, severe skewing, deﬁned as
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pathologic per se. The most common technique used to analyzed XCI
patterns is genotyping of a highly polymorphic CAG repeat in the
human androgen receptor (AR) gene. Hpa II and Hha I enzyme restric-
tion sites, located b100 bp from this polymorphic short tandem re-
peat, are methylated on the inactive X chromosome and non-
methylated on the active X chromosome. Polymerase chain reaction
(PCR) ampliﬁcation across this region permits the distinguishing of
2 amplicons with different sizes, corresponding to maternal and pa-
ternal X alleles. After enzyme digestion, PCR ampliﬁcation is possible
only for the methylated (uncut) X-chromosome. Densitometric anal-
ysis of the 2 alleles indicates the inactivation status of 1 allele com-
pared with the other and reveals the percentage of XCI skewing. A
skewed result is deﬁned as one allele being inactivated at >75%
while extreme skewing represents an inactivation of >90% [39]. In
the general population skewed XCI is sometimes observed, but ex-
treme skewing is rare while being associated with a subgroup of pa-
tients with juvenile idiopathic arthritis [40]. Of note, XCI skewing
increases signiﬁcantly in the blood cells of females from the neonatal
period to old age and XCI skewing is three-times more frequent at
older ages compared to birth [41].
Whether sex hormones during reproductive life (i.e. prepuberty,
puberty, and adults before and after menopause) or immunomodu-
lating treatments commonly used in AID may also have an impact
on XCI skewing remains to be determined despite the available nega-
tive evidence [40,42,43].
As previously mentioned, the new data on additional players such
as small, noncoding RNA (snRNA) and on DNA methylation proﬁling
recently undermined the classical dogma of X-chromosome inactiva-
tion. DNA methylation remains the most studied phenomenon of
gene silencing and X-chromosome inactivation but it has been
reported that, in a counterintuitive fashion [44], the inactive chromo-
some manifests the lower degree of DNA methylation [45], somehow
in conﬂict with the previous data on X inactivation and reversing the
established relationship between overall methylation and expression
potential as such enhanced methylation is concentrated in the gene
body, rather than the promoter [45]. Furthermore, it has been
shown that 10–15% of X-linked genes variably escapes silencing and
are expressed from both X chromosomes in a proportion of healthy
women [46]. Taken altogether, these ﬁndings have radically changed
our understanding of the biology of X chromosomes and allow specif-
ic genes to achieve double or a null expression in physiological condi-
tions [7].3. Of X chromosomes and female advantages
In general terms, females have a longevity advantage compared to
males, and this is true for several mammalian species, including
humans [47]. Additionally, the outcome and survival rates from nu-
merous diseases are signiﬁcantly better for women [48,49]. The X
chromosome is partly responsible for the altered responsiveness of
the female immune system [35] constituting an immunological ad-
vantage. The numerous clinical observations supporting this advan-
tage are now paralleled by theoretical and mathematical models,
which conﬁrm that throughout evolution, males have acquired
lower immune responsiveness than females [50,51]. This is well illus-
trated by the superior capacity of women to produce serum anti-
bodies and IgM following stimuli [52,53]. Furthermore, the
enhanced susceptibility of males to infections is manifest since
birth: male newborns are more prone to septicemia and meningitis,
and have higher incidence rates of tuberculosis [54] or more severe
infections caused by bacteria or viruses, such as respiratory infections
caused by parainﬂuenza virus and respiratory syncytial virus, as well
as those caused by bacteria such as Staphylococcus spp., Escherichia
coli, Legionella pneumophila and Campylobacter spp. [53,55–58].From an evolutionary standpoint it is quite intuitive that the pres-
ence of one X chromosome represents a signiﬁcant disadvantage for
mammalian males, as every newly arisen recessive mutation on the
X chromosome will be phenotypically expressed [35], as well illus-
trated by X-linked diseases [59]. In these conditions, the immune sys-
tem can be impaired at different levels encompassing innate and
adaptive immunity key functions such as infectious agents phagocy-
tosis or lymphocyte differentiation based on the absence or dysfunc-
tion of immune cells or impaired cytokine-mediated signaling
[60–62].
4. Of X chromosomes and the onset of autoimmunity
Some hypotheses have been suggested to explain why X chromo-
some inactivation skewing or other X chromosome-associated abnor-
malities that will be discussed later may contribute to disturbances in
self recognition and ultimately to tolerance breakdown and AID. These
hypotheses include the loss of mosaicism, the reactivation and the hap-
loinsufﬁciency based on ﬁndings in female patients with speciﬁc auto-
immune disorders (an illustration of these mechanisms is provided in
Fig. 1). Nevertheless, the sameAIDmay recognize signs of all or possibly
none of the proposed mechanisms in subgroups of patients. This sug-
gests that these mechanisms are not universal and that the same dis-
ease may manifest different pathogenetic mechanisms.
4.1. Loss of mosaicism
The loss of mosaicism hypothesis states that disturbances in ran-
dom XCI may result in autoimmunity [63–65], as ﬁrst proposed by
Kast [64] and later developed by Stewart [65] and Ozcelik [63].
Women with random mosaicism possess two populations of dendrit-
ic cells (DCs) that express either maternal or paternal X-linked self
antigens for thymic negative selection, and potentially autoreactive
thymocytes are negatively selected by both DC populations. Con-
versely, a woman with severe XCI skewing will have, for example,
the preferential inactivation of the paternal X chromosome. In this
case, T cells will be only tolerized by DCs expressing maternal X-
linked self antigens and autoreactive T cells speciﬁc for paternal X
chromosome self antigens will escape negative selection and enter
the periphery [65]. This hypothesis was supported ﬁrst by the report
of nonspeciﬁc, polyclonal T cell activation in several female patients
with SLE [66]. In this scenario, self antigens encoded by the X chromo-
somemay prime the non-tolerized X-reactive T cells, and these T cells
may thus activate B cells presenting the same endogenous X-
chromosome self antigen [65,67]. It is well established that SLE dis-
ease activity is associated with polyclonal B cell activation and,
according to this model, the ‘polyreactive’ T cells are each speciﬁcally
reactive to a particular B cell-derived X-chromosome-associated self
antigen [65]. Autoimmune thyroid diseases (AITD) and systemic scle-
rosis (SSc) are also associated with a high degree of XCI skewing de-
spite the fact that the AR gene was used to determine the XCI pattern
thus limiting the value of this observation [68–71]. Conversely, pa-
tients with Sjögren's syndrome and PBC do not have X chromosome
inactivation skewing in blood cells, indicating that this is not a com-
mon characteristic of all autoimmune diseases [63,72]. Moreover,
even if skewed inactivation pattern is a common feature of women af-
fected by autoimmune diseases, it does not necessarily lead to auto-
immunity in all women, as XCI patterns in peripheral lymphocytes
from women with SLE, multiple sclerosis, or RA are similar to age-
matched healthy women [73]. A second line of evidence to support
this hypothesis is provided by the observation that men with a XXY
karyotype (i.e. Klinefelter's syndrome) have a 14-fold higher risk of
developing SLE than XY men [74]. In this case, it has been suggested
that one of the X chromosomes of XXY men is subject to inactivation,
and evidence shows that XCI skewing is a common characteristic of
Klinefelter's syndrome, thus ultimately leading to disease onset [65].
Fig. 1. A schematic view of the loss of mosaicism hypothesis. The extreme skewing of X chromosome inactivation (represented on the right) causes the breakdown of self tolerance
in the thymus and the persistence of autoreactive lymphocytes for X-linked antigens.
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According to this second hypothesis, the reactivation of genes
from the inactive X chromosome may contribute to autoimmunity
[75]. The mechanisms leading to inactive X chromosome reactivation
remain enigmatic but this could lead to overexpression of X-linked
genes involved in immune functions, which in turn would be respon-
sible for overproduction of autoantibodies [76] or tolerance break-
down, as in the case of FoxP3 [77]. Alternatively, overexpression of
X-linked genes could disrupt the equilibrium in the mechanism of
ﬁne-tuning protein expression and generate protein aggregates that
would trigger responses against self antigens [78]. Reactivation of
CD40L on the inactive X chromosome has been found in T cells of fe-
male patients with SLE [76,79] and its methylation appears to play a
major role in determining the serum polyclonal hyper-IgM character-
izing PBC [80]. It was proposed that regulatory sequences on the inac-
tive X chromosome would be demethylated in T cells from these
patients, resulting in CD40L overexpression [76]. Indeed, CD4+ T
cells from female patients with SLE express two-fold higher CD40L
than males, and these CD40L overexpressing CD4+ T cells stimulate
an increased IgG production by autologous B cells correlating with
SLE disease activity [79]. Similar gene dosage effects may be the con-
sequence of other changes not resulting in the reactivation of methyl-
ated X-linked genes. The duplication of the Tlr7 gene is associated
with an SLE-like disease in mice [81] while XX female mice are
more susceptible to pristane-induced SLE and experimental autoim-
mune encephalomyelitis as a model of multiple sclerosis than
XYSry-female mice (with an inserted Sry transgene) [82]. Female
mice had identical gonadal and hormonal background, which sug-
gests that double dosage of the X chromosome may itself confer sus-
ceptibility to autoimmunity.
4.3. Haploinsufﬁciency
A third hypothesis states that haploinsufﬁciency for X-linked
genes results in AID development [83,84], as ﬁrst suggested by theobservation that patients with X chromosome monosomy (loss of
one X chromosome; X0 karyotype), such as those with Turner's syn-
drome, commonly manifest immune changes [85]. Turner's syndrome
is characterized by the absence of all or part of one of the X chromo-
somes, and women with this syndrome have, for example, an in-
creased risk of developing AITD and inﬂammatory bowel diseases
[86,87]. The haploinsufﬁciency of genes located in the pseudoautoso-
mal region (PAR) 1 of sex chromosomes has been proposed to con-
tribute to the defects observed in Turner's syndrome [88] and these
genes, present in two copies in both XX females and XY males, are
only present in one copy in X0 females, and this may be functionally
insufﬁcient. PAR 1 contains 26 genes and, although some have been
associated with the mental retardation observed in Turner's syn-
drome, only few are involved in immune functions. Women with
isochromosome-Xq are also more prone to developing AITD and in-
ﬂammatory bowel diseases, also suggesting that an imbalanced ex-
pression of genes from the short arm of the X chromosome may be
a predisposing factor for developing these disorders [86]. More re-
cently, AID with a female predominance and a late-age onset such
as PBC, SSc, and AITD were reported to be characterized by a higher
X chromosome monosomy rate in peripheral B and T cells, suggesting
again that haploinsufﬁciency for X-linked genes may be a crucial fac-
tor [83,89,90]. The mechanism behind loss of one X chromosome
from these cells is not known but appears to increase with age, a phe-
nomenon commonly observed in healthy women. It has been pro-
posed that a gradually acquired haploinsufﬁciency for speciﬁc X
chromosome-linked genes (from PAR or genes that permanently es-
cape inactivation in normal females) in peripheral B and T cells
could be responsible for the generation of autoantibodies [89]. De-
spite these theories, few genes contained in the X chromosome
have been speciﬁcally associated with one or more AID. However, it
is unlikely that mutations or different methylation in a single gene
would be responsible for the higher susceptibility of females to auto-
immunity, as recently illustrated in female twins with PBC [91]. In
this study the X chromosome genes variably escaping inactivation
were compared in terms of expression and methylation between
Table 2
X chromosome abnormalities reported in autoimmune diseases including systemic lupus erythematosus (SLE), autoimmune thyroid disease (AITD), primary biliary cirrhosis (PBC),
and systemic sclerosis (SSc).
Site Clinical phenotype References
Xp22.33 Xp22.33;Yp11.2 translocation causing
triplication of genes
Severe SLE [115]
Xq26 Demethylation of CD40LG on the Xi in
T cells in women, leading to over-expression
of CD40LG in CD4+ T cells.
SLE [76]
X, AR gene Skewed X chromosome inactivation AITD, SSc [68,69]
X, 4 sites Random X chromosome inactivation PBC [116]
Xp11.23 Mutated JM2 fork head-related protein X-linked autoimmunity-allergic
dysregulation syndrome
[117]
X, speciﬁc site
not identiﬁed
Chromosomal abnormalities in peripheral
blood cells. Half of MS abnormalities were
X-related.
Multiple sclerosis [118]
Xp21.2 Various defects in cytochrome B β subunit
and carriers of X-linked chronic
granulomatous disease
SLE-like symptoms in some female carriers
and some male patients with X-CGD.
[108,119]
X, duplication Higher incidence of lupus in males with
Klinefelter's syndrome (XXY)
SLE [120]
X, monosomy Higher frequency in peripheral T and B
cells from female patients
PBC, SSc, AITD [84,90,109]
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gested that CLIC2 and PIN4 may be associated with the disease
through epigenetic mechanisms.
4.4. Epigenetics and polyamines
Numerous AID, including SLE and RA, are characterized by an abnor-
mal methylation pattern of their lymphocyte DNA [44]. As a ﬁnal topic
for our discussion, we will touch on a hypothesis that relates loss of X-
linked dosage compensation to the alterations in methylation observed
in AID [92] and,more speciﬁcally, the elevated levels of polyamines. Poly-
amines are ubiquitous small ﬂexible cations that are essential for cell
growth and proliferation [93,94]. The charge distribution and length of
polyamines give them the potential for unique interactions, such as con-
necting anionic points in intramolecular and intermolecular complexes.
Their putative functions and interactions include the histone acetylation
[95], themaintenance of the blood–brain andblood–nerve barrier perme-
ability [96], themodulation of ion channels [97], themodulation of nucle-
ar receptor interactions, such as increasing the afﬁnity of estrogen
receptor for DNA [98] [99], DNA repair [100], and stabilizing Z-DNA
[101]. Because of the importance of polyamines, the synthesis and recy-
cling of polyamines are tightly controlled processes, particularly for sper-
midine and spermine, and their precursor, putrescine. A hypothesis has
been proposed that explains some autoimmune diseases as occurring
due to loss of dosage compensation of X-linked polyamine genes at
Xp22.1, which impact intracellular methylation [102] with unpredictable
effects. The two genes of interest are spermine synthase (SMS), an en-
zyme involved in synthesizing spermine from spermidine; and spermi-
dine/spermine-N1-acetyltransferase (SAT1), an enzyme involved in
recycling spermine and spermidine. Overexpression of SMS would lead
to increased levels of spermine, particularly when unbound spermidine
is available, as under cellular stress conditions (ex. UV light or viral activ-
ity). Over-expression of SAT1 increases recycling of polyamines. Increased
polyamine synthesis uses decarboxylated S-adenosylmethionine
(dcSAM), created from S-adenosylmethionine (SAM) by SAMDC. The
resulting decrease in SAM, the cell methyl donor, would ultimately affect
themethylation of DNA in the nucleus thus ﬁtting in the proposedmodel
for AID [103–105].
5. The unifying hypothesis of X chromosome vulnerability
The vulnerability of the X chromosomemay constitute the missing
link to unite all previously discussed hypotheses for AID sex predom-
inance which are summarized in Table 2. As mentioned, dosagecompensation is the fundamental purpose of XCI and its loss may be
restricted to a few genes at the abnormality site or be more extensive
[92]. First, one SLE case was observed in an XX man who had an
Xp22.33;Yp11.2 translocation that resulted in duplication of PAR1
genes and a partial trisomy of some genes, most interestingly, the
translocation included the genes for the alpha subunit of the
interleukin-3 receptor (IL-3 being a growth factor for proliferation
and differentiation of hematopoietic stem cells) and CD99 (a trans-
membrane protein involved in adhesion and apoptosis of T cells)
[106]. Second, a gene dose effect could also be mediated by XCI-
escaping genes that will have a variable degree of expression in
women [107], as discussed for PBC [91]. Third, a different hint at the
vulnerability of the X chromosome is gathered from X-linked chronic
granulomatous disease (X-CGD), an X-linked recessive disease affect-
ing phagocytes that impairs the capacity to generate superoxide an-
ions that are converted to hydroxyl radicals, hydrogen peroxide, and
other radicals. These oxidants are crucial to counteract and destroy
infectious agents (particularly bacteria) ingested by phagocytes and
patients are thus immunocompromised and prone to bacterial infec-
tions. The disease is associated with the cytochrome B β subunit
gene (CYBB) mapping at Xp21.2; which explains why only men are
affected. Of relevance to the present discussion, there are numerous
reports of SLE-like symptoms in X-CGD patients and mothers who
carry the X-CGD mutation [108]. This observation may suggest that
Xp21.2 mutations may trigger the overexpression of genes from
that region [92]. Fourth, we submit that the enhanced X chromosome
monosomy observed in women with late-onset AID also supports our
hypothesis. The later observation that such a phenomenon was not
common to a prototypic disease for early-onset such as SLE [109] ap-
pears to conﬁrm that the high replication rate of lymphocytes may ac-
cumulate transcription errors over the years thus favoring tolerance
breakdown if the X chromosome is affected [110].
6. Final remarks and future developments
Why women? Following efforts in sex hormones and other female-
limited factors, the past decade has provided numerous lines of evi-
dence to potentially explain the female predominance of autoimmune
diseases.Whilewemust acknowledge that the current clinical epidemi-
ology providing the known sex ratios illustrated in Table 1 may be bur-
dened by various ﬂaws that include disease awareness and other types
of physician-related bias (possibly including socioeconomic factors in
mainly private health care systems). As an example, while we recognize
that the female to male ratio is signiﬁcantly higher for identiﬁed PBC
A536 C. Selmi et al. / Autoimmunity Reviews 11 (2012) A531–A537cases compared to the prevalence of the highly speciﬁc autoantibody [6]
we should also note that physicians are biased toward diagnoses that
are more pertinent to a speciﬁc sex, as in the case of coronary heart dis-
ease inmen [111]. Accordingly, we are in need of true population-based
epidemiology to determine the sex ratio in incident cases and not only
in tertiary care centers inwhich one sex could be under-represented, as
well represented by the variable ratios observed for type 1 diabetes in
different age groups and geographical areas [112]. Similarly, we are
convinced that only a multidisciplinary approach ranging from epige-
netics [113] to the growing area of microRNA [114], from next-
generation genomics to exone sequencing, from serum autoantibodies
to clinical phenotyping with appropriate classiﬁcation criteria will pro-
vide solid answers to what is perhaps amore appropriate question such
as: why not men?
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